Concepedia

Author

Jing Li

General Hospital of Shenyang Military RegionORCID

Also Known As

Jing Li, Ling Ren, Zizhao Qi

31

Publications

273

Citations

10

H-Index

18

Concepts

All Affiliations

General Hospital of Shenyang Military RegionSecond Affiliated Hospital of Dalian Medical UniversityDalian Medical University
JL

About

Jing Li is an author at General Hospital of Shenyang Military Region specializing in medicine, health sciences, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

2

2

24

2

Medicine

2

2

24

3

Clinical Nutrition

1

1

11

4

Emergency Medicine

1

1

13

5

Nutrition

1

1

11

Jing Li

×

11

Publications

172

Citations

10

H-Index

YearCitations

Pharmacodynamics and pharmacokinetics of ticagrelor <i>vs</i>. clopidogrel in patients with acute coronary syndromes and chronic kidney disease

Heyang Wang, Jing Qi, Yi Li,

British Journal of Clinical Pharmacology

2017

34

Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Heyang Wang, Yi Li, Xiaoming Xu,

Chinese Medical Journal

2018

26

Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel

Ruoxi Gu, Xiaozeng Wang, Jing Li,

Military Medical Research

2016

17

Dietary Inflammatory Index and All-Cause Mortality in Older Adults with Hypertension: Results from NHANES

Yang Cao, Pengxiao Li, Yan Zhang,

Journal of Clinical Medicine

2023

16

Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study.

Hong-Chang Zhu, Yi Li, Shao-Yi Guan,

PubMed

2015

13

Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial

Yi Li, Quanmin Jing, Bing Wang,

American Heart Journal

2020

13

Distribution of <i>CYP2C19</i>, <i>ABCB1</i> and <i>PON1</i> polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease

Lijuan Ma, Yuan Yuan, Jing Li,

International Journal of Immunogenetics

2020

12

The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR‐1 Antagonist, in Healthy Adult Subjects

Martin O. Behm, Teddy Kosoglou, André M. M. Miltenburg,

Clinical Pharmacology in Drug Development

2013

11

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects

Xia Chen, Teddy Kosoglou, Paul Statkevich,

International Journal of Clinical Pharmacology and Therapeutics

2014

10

Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention

Yuzhuo Li, Jing Li, Miaohan Qiu,

Catheterization and Cardiovascular Interventions

2022

10

Page 1